Medical Device

National law firm Barr Law Group is investigating the actions of the officers and board of directors of Vanda Pharmaceuticals Inc., Velodyne Lidar, Inc., Lordstown Motors Corporation, and Abbott Laboratories.   If you are a current owner of shares of any of these stocks, contact leo@barrlaw.com or call (619) 400-4966.

Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) Shareholder Lawsuit Update

Barr Law Group is investigating Vanda Pharmaceuticals Inc. regarding possible breaches of fiduciary duties and other violations of law, including securities claims on behalf of shareholders. On March 10, 2021, Judge Frederic Block of the United States District Court for the Eastern District of New York issued an order denying the company's motion to dismiss in the pending securities class action, paving the way for litigation to proceed. According to the complaint against Vanda Pharmaceuticals for alleged violations of the Securities Exchange Act of 1934, defendants misled investors about the company's competitive advantage and hid that the company was engaged in a fraudulent scheme in which the company promoted the off-label use of two primary products that treat central nervous system disorders — Fanapt and Hetlioz. To learn more about this investigation and your rights, visit: http://barrlaw.com/investor-contact . Representation is contingency based, no out of pocket costs.

Velodyne Lidar, Inc. (NASDAQ: VLDR) Shareholder Rights Investigation

Barr Law Group is investigating Velodyne Lidar, Inc. regarding possible breaches of fiduciary duties and other violations of law, including securities claims on behalf of shareholders. On February 22, 2021, Velodyne announced that the Board had "removed David Hall as Chairman of the Board and terminated Marta Hall's employment as Chief Marketing Officer of the Company" after the Audit Committee's investigation "concluded that Mr. Hall and Ms. Hall each behaved inappropriately with regard to certain Board and Company processes, and failed to operate with respect, honesty, integrity, and candor in their dealings with Company officers and directors." In addition, the Company announced that Velodyne's Board formally censured Mr. Hall and Ms. Hall, but that they would remain directors of Velodyne.   On this news, Velodyne's common stock fell $3.14, or approximately 15%, to close at $17.97 per share on February 22, 2021, on unusually heavy trading volume. Additionally, Velodyne's warrants fell $1.47, or approximately 20%, to close at $5.90 per warrant on February 22, 2021. Velodyne's stock price has continued to fall, currently trading around $14 per share.   To learn more about this investigation and your rights, visit: http://barrlaw.com/investor-contact . Representation is contingency based, no out of pocket costs.

Lordstown Motors Corporation (NASDAQ: RIDE) Shareholder Rights Investigation

Barr Law Group is investigating Lordstown Motors Corporation regarding possible breaches of fiduciary duties and other violations of law by the company's officers and directors. On March 12, Hindenburg Research put out a report noting: "Lordstown is an electric vehicle SPAC with no revenue and no sellable product, which we believe has misled investors on both its demand and production capabilities."   Hindenburg also noted, "Our conversations with former employees, business partners and an extensive document review show that the company's orders are largely fictitious and used as a prop to raise capital and confer legitimacy."   On this news, Lordstown was down over 16%.   To learn more about this investigation and your rights, visit: http://barrlaw.com/investor-contact . Representation is contingency based, no out of pocket costs.

Abbott Laboratories (NYSE: ABT) Shareholder Rights Investigation

Barr Law Group is investigating Abbott Laboratories regarding possible breaches of fiduciary duties and other violations of law by the company's officers and directors. To learn more about this investigation and your rights, visit: http://barrlaw.com/investor-contact . Representation is contingency based, no out of pocket costs.

Concerned shareholders are encouraged to contact Leo Kandinov to learn more:

leo@barrlaw.com
(619) 400-4966
www.barrlaw.com

Barr Law Group is a boutique law firm consisting of highly experienced and specialized litigators who represent investors in securities litigation and corporate governance matters. The firm would be happy to further discuss these matters, and any legal rights or remedies potentially available to you, at no charge.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contact:

Leo Kandinov, Partner
leo@barrlaw.com
619-400-4966
501 W Broadway Suite 800
San Diego, CA 92101
www.barrlaw.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

Thermo Fisher Scientific and Structura Biotechnology Collaborate to Offer a Solution for Real-Time Cryo-EM Data Analysis

New Embedded CryoSPARC Live software to be made available by Structura and Thermo Fisher and designed to integrate with Thermo Fisher technology

Thermo Fisher Scientific Inc., the world leader in serving science, and Structura Biotechnology Inc., a leading provider of cryo-EM data analysis software, today announced a collaboration to make available a new single particle analysis software solution, a version of Structura's CryoSPARC Live, that is designed to integrate with Thermo Fisher's Smart EPU software and cryo-transmission electron microscope (cryo-TEM) technology. The new solution, Embedded CryoSPARC Live , will be offered as a subscription.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Viemed Healthcare Announces Second Quarter 2022 Financial Results

Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD and TSX:VMD.TO), a national leader in respiratory care and technology-enabled home medical equipment services, announced today that it has reported its financial results for the three and six months ended June 30, 2022.

Operational highlights (all dollar amounts are USD):

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Johnson & Johnson to Participate in the 2022 Wells Fargo Securities Healthcare Conference

Johnson & Johnson (NYSE: JNJ) will participate in the 2022 Wells Fargo Securities Healthcare Conference at the Encore Boston Harbor in Everett, MA on Wednesday, September 7 th . Ashley McEvoy, Executive Vice President, Worldwide Chairman, MedTech will represent the Company in a session scheduled at 11:00 a.m. (Eastern Time).

This conference call will be available to investors and other interested parties by visiting the Johnson & Johnson website at www.investor.jnj.com .

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Viemed Announces Executive Additions to Lead Acquisition Growth

Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD and TSX:VMD.TO), a national leader in respiratory care and technology-enabled home medical equipment services, announced the additions of Michael Freeman as Chief Business Development Officer and Jeremy Trahan as Chief Legal Officer and Executive Vice President of Acquisitions and Strategic Transactions. Prior to joining the team at Viemed, Freeman and Trahan were executives at LHC Group, Inc ("LHC")(NASDAQ:LHCG), where together they directed and were integrally involved in over 100 transactions valued at approximately $1.9 billion, collectively.

"We are thrilled to expand our team of extremely talented executives by welcoming Michael and Jeremy," said Casey Hoyt, Viemed Chief Executive Officer. "Together, they have a proven track record of success and their leadership and experience will support a strong acquisition infrastructure within our organization. I am confident that they will play a critical role in the next major chapter of our organizational growth."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
ALR Technologies Announces First Shipment of GluCurve Pet CGMs Expected in October and Update on the Manufacturing Agreement

ALR Technologies Announces First Shipment of GluCurve Pet CGMs Expected in October and Update on the Manufacturing Agreement

ALR Technologies SG Pte. Ltd ("ALRT" or the "Company") (OTCQB: ALRT), the diabetes management company, announces the Company has received manufacturing approval from Infinovo Medical Co., Ltd. ("Infinovo") to place the first purchase order ("PO") for the GluCurve Pet CGM with an expected delivery date of October 2022. Furthermore, the manufacturing and supply agreement with Infinovo was subject to certain closing conditions, including entering into a binding sales and distribution agreement for the GluCurve Pet CGM by July 31, 2022. Both parties agreed to let that agreement terminate and are now working on completing a new agreement under the same terms, extending the closing condition for ALRT to enter into a binding sales and distribution agreement for GluCurve to August 31, 2022.

"We have agreed in principle on the key terms for a global sales and distribution agreement with a leading animal health company," commented Joe Stern, Head of Animal Health at ALRT. "The last step in their due diligence process is to evaluate the GluCurve Pet CGM internally by using it on their own sample of customers and their respective pets. This step is taking longer than we initially projected due to scheduling delays. After discussing the delays with Infinovo we agreed it would be in both parties' best interest to complete a new contract extending the date of the closing condition for a sales and distribution agreement date to August 31, 2022. Based on our non-inferiority study results earlier this year, we do not expect this delay to alter our commercialization schedule and will provide further updates on timing and details of the initial launch upon the execution of the global sales and distribution agreement."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Bausch Health Provides Update Following Oral Order in XIFAXAN® Patent Litigation

-- Company to Appeal Expected Court Decision on Certain XIFAXAN® Patents –

Bausch Health Companies Inc. (NYSETSX: BHC), and its gastroenterology business Salix Pharmaceuticals, today announced the U.S. District Court of Delaware issued an Oral Order in the matter of Salix Pharmaceuticals, Ltd. et al v. Norwich Pharmaceuticals, Inc. regarding the infringement and validity of certain U.S. Patents protecting the composition and use of XIFAXAN® (rifaximin) 550 mg tablets for the treatment of irritable bowel syndrome with diarrhea (IBS-D) and reduction in risk of overt hepatic encephalopathy (HE) recurrence.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×